Live Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
BMC Cancer. 2012 Jan 16;12:17. doi: 10.1186/1471-2407-12-17.
There have been conflicting reports about serum golgi protein 73 (GP73) as one of the most promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC.
After a systematic review of related studies, sensitivity, specificity and other measures about the accuracy of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve analysis was used to summarize the overall test performance.
Eight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs. 70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87).
The current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.
关于高尔基体蛋白 73（GP73）作为肝细胞癌（HCC）诊断最有前途的血清标志物之一，存在相互矛盾的报道。本研究旨在对血清 GP73 与甲胎蛋白（AFP）诊断 HCC 的准确性进行系统评价。
对相关研究进行系统评价后，使用随机效应模型汇总血清 GP73 和 AFP 对 HCC 诊断准确性的灵敏度、特异性和其他指标。采用综合受试者工作特征曲线分析来总结总体试验性能。
本荟萃分析纳入 8 项研究。纳入研究中血清 GP73 和 AFP 诊断 HCC 的汇总估计值如下：灵敏度为 76%（95%可信区间 51%-91%）vs. 70%（47%-86%）；特异性为 86%（95%可信区间 65%-95%）vs. 89%（69%-96%）；诊断比值比（DOR）为 18.59（95%可信区间 5.33-64.91）vs. 18.00（9.41-34.46）；以及 sROC 曲线下面积为 0.88（95%可信区间 0.77-0.99）vs. 0.86（95%可信区间 0.84-0.87）。
目前的证据表明，血清 GP73 诊断 HCC 的准确性与 AFP 相当，而血清 GP73 联合 AFP 检测 HCC 的价值值得进一步研究。
